Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Last Name

Contact Us
If you have any questions or feedback please contact us.

Kathrin Bernt

TitleElectronic Research Admin
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus

    Collapse Research 
    Collapse research activities and funding
    K08HL102264     (BERNT, KATHRIN M)Aug 1, 2010 - Jul 31, 2015
    H3K79 Methylation in Hematopoietic Stem Cell Development and MLL-Rearranged Leuk
    Role: Principal Investigator

    R01CA201230     (BERNT, KATHRIN M)Dec 16, 2015 - Apr 30, 2021
    The role of H3K79 methylation in IDH-mutant leukemia
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Bernt KM, Neff T. The role of polycomb repressive complex 2 in early T-cell precursor acute lymphoblastic leukemia. Mol Cell Oncol. 2018; 5(5):e1166309. PMID: 30263933.
      View in: PubMed
    2. Campbell CT, Haladyna JN, Drubin DA, Thomson TM, Maria MJ, Yamauchi T, Waters NJ, Olhava EJ, Pollock RM, Smith JJ, Copeland RA, Blakemore SJ, Bernt KM, Daigle SR. Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in MLL-Rearranged Leukemia. Mol Cancer Ther. 2017 08; 16(8):1669-1679. PMID: 28428443.
      View in: PubMed
    3. Winters AC, Bernt KM. MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. Front Pediatr. 2017; 5:4. PMID: 28232907.
      View in: PubMed
    4. Bernt KM, Hunger SP, Neff T. The Functional Role of PRC2 in Early T-cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) - Mechanisms and Opportunities. Front Pediatr. 2016; 4:49. PMID: 27242978; PMCID: PMC4870860.
    5. Haladyna JN, Pastuer T, Riedel SS, Perraud AL, Bernt KM. Transient potential receptor melastatin-2 (Trpm2) does not influence murine MLL-AF9-driven AML leukemogenesis or in vitro response to chemotherapy. Exp Hematol. 2016 07; 44(7):596-602.e3. PMID: 27033163.
      View in: PubMed
    6. Riedel SS, Haladyna JN, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Pollock RM, Daigle SR, Jordan CT, Ernst P, Neff T, Bernt KM. MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. J Clin Invest. 2016 Apr 01; 126(4):1438-50. PMID: 26927674.
      View in: PubMed
    7. Danis E, Yamauchi T, Echanique K, Zhang X, Haladyna JN, Riedel SS, Zhu N, Xie H, Orkin SH, Armstrong SA, Bernt KM, Neff T. Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia. Cell Rep. 2016 Mar 01; 14(8):1953-65. PMID: 26904942; PMCID: PMC4790111.
    8. Riedel SS, Neff T, Bernt KM. Histone profiles in cancer. Pharmacol Ther. 2015 Oct; 154:87-109. PMID: 26210403.
      View in: PubMed
    9. Danis E, Yamauchi T, Echanique K, Haladyna J, Kalkur R, Riedel S, Zhu N, Xie H, Bernt KM, Orkin SH, Armstrong SA, Neff T. Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model. Exp Hematol. 2015 Nov; 43(11):930-935.e6. PMID: 26118502; PMCID: PMC4630114 [Available on 11/01/16].
    10. Chen CW, Koche RP, Sinha AU, Deshpande AJ, Zhu N, Eng R, Doench JG, Xu H, Chu SH, Qi J, Wang X, Delaney C, Bernt KM, Root DE, Hahn WC, Bradner JE, Armstrong SA. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat Med. 2015 Apr; 21(4):335-43. PMID: 25822366; PMCID: PMC4390532.
    11. Haladyna JN, Yamauchi T, Neff T, Bernt KM. Epigenetic modifiers in normal and malignant hematopoiesis. Epigenomics. 2015; 7(2):301-20. PMID: 25942537.
      View in: PubMed
    12. Deshpande AJ, Deshpande A, Sinha AU, Chen L, Chang J, Cihan A, Fazio M, Chen CW, Zhu N, Koche R, Dzhekieva L, Ibáñez G, Dias S, Banka D, Krivtsov A, Luo M, Roeder RG, Bradner JE, Bernt KM, Armstrong SA. AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell. 2014 Dec 08; 26(6):896-908. PMID: 25464900; PMCID: PMC4291116.
    13. Bernt KM, Hunger SP. Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Oncol. 2014; 4:54. PMID: 24724051; PMCID: PMC3971203.
    14. Bernt KM. HDAC expression patterns in pediatric ALL. Leuk Res. 2013 Oct; 37(10):1191-2. PMID: 23962567.
      View in: PubMed
    15. Ho LL, Sinha A, Verzi M, Bernt KM, Armstrong SA, Shivdasani RA. DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-specific and other intestinal epithelial functions. Mol Cell Biol. 2013 May; 33(9):1735-45. PMID: 23428873; PMCID: PMC3624170.
    16. Deshpande AJ, Chen L, Fazio M, Sinha AU, Bernt KM, Banka D, Dias S, Chang J, Olhava EJ, Daigle SR, Richon VM, Pollock RM, Armstrong SA. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood. 2013 Mar 28; 121(13):2533-41. PMID: 23361907.
      View in: PubMed
    17. Chen L, Deshpande AJ, Banka D, Bernt KM, Dias S, Buske C, Olhava EJ, Daigle SR, Richon VM, Pollock RM, Armstrong SA. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia. 2013 Apr; 27(4):813-22. PMID: 23138183.
      View in: PubMed
    18. Onder TT, Kara N, Cherry A, Sinha AU, Zhu N, Bernt KM, Cahan P, Marcarci BO, Unternaehrer J, Gupta PB, Lander ES, Armstrong SA, Daley GQ. Chromatin-modifying enzymes as modulators of reprogramming. Nature. 2012 Mar 04; 483(7391):598-602. PMID: 22388813; PMCID: PMC3501145.
    19. Bernt KM, Armstrong SA. A role for DOT1L in MLL-rearranged leukemias. Epigenomics. 2011 Dec; 3(6):667-70. PMID: 22126283.
      View in: PubMed
    20. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L, Pollock RM, Richon VM, Kung AL, Armstrong SA. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011 Jul 12; 20(1):66-78. PMID: 21741597; PMCID: PMC3329803.
    21. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, Johnston LD, Scott MP, Smith JJ, Xiao Y, Jin L, Kuntz KW, Chesworth R, Moyer MP, Bernt KM, Tseng JC, Kung AL, Armstrong SA, Copeland RA, Richon VM, Pollock RM. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011 Jul 12; 20(1):53-65. PMID: 21741596; PMCID: PMC4046888.
    22. Bernt KM, Armstrong SA. Targeting epigenetic programs in MLL-rearranged leukemias. Hematology Am Soc Hematol Educ Program. 2011; 2011:354-60. PMID: 22160057.
      View in: PubMed
    23. Bernt KM, Prokop A, Huebener N, Gaedicke G, Wrasidlo W, Lode HN. Eradication of CD19+ leukemia by targeted calicheamicin ?. Bioconjug Chem. 2009 Aug 19; 20(8):1587-94. PMID: 19572629.
      View in: PubMed
    24. Bernt KM, Armstrong SA. Leukemia stem cells and human acute lymphoblastic leukemia. Semin Hematol. 2009 Jan; 46(1):33-8. PMID: 19100366; PMCID: PMC4031465.
    25. Tuve S, Wang H, Ware C, Liu Y, Gaggar A, Bernt K, Shayakhmetov D, Li Z, Strauss R, Stone D, Lieber A. A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J Virol. 2006 Dec; 80(24):12109-20. PMID: 17020944; PMCID: PMC1676274.
    26. Ni S, Bernt K, Gaggar A, Li ZY, Kiem HP, Lieber A. Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum Gene Ther. 2005 Jun; 16(6):664-77. PMID: 15960598; PMCID: PMC1351080.
    27. Bernt KM, Ni S, Tieu AT, Lieber A. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Cancer Res. 2005 May 15; 65(10):4343-52. PMID: 15899826.
      View in: PubMed
    28. Sova P, Ren XW, Ni S, Bernt KM, Mi J, Kiviat N, Lieber A. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther. 2004 Apr; 9(4):496-509. PMID: 15093180.
      View in: PubMed
    29. Bernt KM, Ni S, Gaggar A, Li ZY, Shayakhmetov DM, Lieber A. The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. Mol Ther. 2003 Nov; 8(5):746-55. PMID: 14599807.
      View in: PubMed
    30. Schroeder U, Bernt KM, Lange B, Wenkel J, Jikai J, Shabat D, Amir R, Huebener N, Niethammer AG, Hagemeier C, Wiebusch L, Gaedicke G, Wrasidlo W, Reisfeld RA, Lode HN. Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia. Blood. 2003 Jul 01; 102(1):246-53. PMID: 12623853.
      View in: PubMed
    31. Bernt KM, Steinwaerder DS, Ni S, Li ZY, Roffler SR, Lieber A. Enzyme-activated Prodrug Therapy Enhances Tumor-specific Replication of Adenovirus Vectors. Cancer Res. 2002 Nov 01; 62(21):6089-98. PMID: 12414633.
      View in: PubMed
    32. Bernt K, Liang M, Ye X, Ni S, Li ZY, Ye SL, Hu F, Lieber A. A new type of adenovirus vector that utilizes homologous recombination to achieve tumor-specific replication. J Virol. 2002 Nov; 76(21):10994-1002. PMID: 12368342; PMCID: PMC136641.
    33. Wrasidlo W, Schröder U, Bernt K, Hübener N, Shabat D, Gaedicke G, Lode H. Synthesis, hydrolytic activation and cytotoxicity of etoposide prodrugs. Bioorg Med Chem Lett. 2002 Feb 25; 12(4):557-60. PMID: 11844671.
      View in: PubMed
    34. Bernt K, Walker WA. Human milk and the response of intestinal epithelium to infection. Adv Exp Med Biol. 2001; 501:11-30. PMID: 11787672.
      View in: PubMed
    35. Bernt KM, Walker WA. Human milk as a carrier of biochemical messages. Acta Paediatr Suppl. 1999 Aug; 88(430):27-41. PMID: 10569221.
      View in: PubMed
    Bernt's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description
    Physical Neighbors Expand Description

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)